STJ Minister demands Union and Anvisa to execute the Action Plan for the medicinal cultivation of the plant

Partnership includes two products authorized by Anvisa

Federal University of Viçosa seeks authorization from Anvisa for large-scale cultivation

The twelfth product approved by Anvisa, which will start being distributed at the end of May, is Zion Medpharma's Cannabis sativa Extract

Imported product with medical prescription and authorization from Anvisa is being held by Federal Revenue at Gollog cargo terminal in Guarulhos

Experts analyze the scenario and highlight that the measure meets Anvisa's expectations for the Brazilian market; Analysis reveals that the new legislation does not represent prohibition, but rather a restructuring of the sector focusing on taxation and pharmaceutical control

In practice, Marconi established a total deadline of up to 4 months for Abrace to make the adjustments required by Anvisa, which, according to the federal agency, motivated the request for a suspension injunction that would interrupt the entity's work.

Companies report delays in the release of shipments, while official data from Anvisa indicates reduced average timelines and a high approval rate

Minister Regina Helena Costa states that this will be the last extension and orders Anvisa to report compliance with each intermediate step of the plan

Company demands urgent measures in face of new missed deadlines by the government and Anvisa and proposes experimental environment under judicial supervision

The use of medicinal cannabis in pets has been growing in Brazil since Anvisa's authorization in 2024, bringing relief for chronic pain, epilepsy, and anxiety in animals, and renewed hope for pet owners

Unrestricted prohibitions on Cannabis products currently in force are not in line with Anvisa's regulatory microsystem.

Droga Raia is announcing on its website the first cannabis-based product authorized by Anvisa from the Prati-Donaduzzi laboratory

Director of Institutional Relations evaluates national cultivation, new RDCs from Anvisa, and the challenges to consolidate the sector in the country

COFFITO Ruling No. 735/2024 authorizes physical therapists with specific training to prescribe medications and supplies; however, Anvisa recognizes only doctors and dentists as prescribers of cannabis for medicinal purposes

Working Group brings together experts from across the country to deliver a Technical Note to the Ministry of Health and Anvisa by August

The historic investment from the Financier of Studies and Projects (Finep) will finance cutting-edge structures in two regions of the country. The approval, combined with recent authorizations from Anvisa, boosts the development of the scientific bases of the "CBD Brazil" project with the central goal of reducing the costs of medicinal products in Brazil, subsidizing the national production chain

Brazilian delegation led by Abiquifi participates in a mission to Colombia to exchange experiences on the regulation of cannabis cultivation, with representatives from MAPA, Anvisa, Embrapa, and major pharmaceutical industries

Expansion of the institute in the sector, however, depends on new authorizations from Anvisa for the quality control of plant-based raw materials

Studies show efficacy of cannabinoids in controlling inflammation, acne, and itching, while Anvisa evaluates expanding regulations for topical products